Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
Asymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require antibodies with reduced or silenced effector functio...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-05-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | http://www.mdpi.com/2073-4468/6/2/7 |
id |
doaj-be9716f33f7146518d70ed30b1763cf2 |
---|---|
record_format |
Article |
spelling |
doaj-be9716f33f7146518d70ed30b1763cf22020-11-24T22:23:53ZengMDPI AGAntibodies2073-44682017-05-0162710.3390/antib6020007antib6020007Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector FunctionEric Escobar-Cabrera0Paula Lario1Jason Baardsnes2Joseph Schrag3Yves Durocher4Surjit Dixit5Zymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, CanadaZymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, CanadaHuman Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, CanadaHuman Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, CanadaHuman Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, CanadaZymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, CanadaAsymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require antibodies with reduced or silenced effector function. Although many solutions have been described in the literature to knockout effector function, to date all of them have involved the use of a specific antibody subtype (e.g., IgG2 or IgG4), or symmetric mutations in the lower hinge or CH2 domain of traditional homodimeric monospecific antibodies. In the context of a heterodimeric Fc, we describe novel asymmetric Fc mutations with reduced or silenced effector function in this article. These heteromultimeric designs contain asymmetric charged mutations in the lower hinge and the CH2 domain of the Fc. Surface plasmon resonance showed that the designed mutations display much reduced binding to all of the Fc gamma receptors and C1q. Ex vivo ADCC and CDC assays showed a consistent reduction in activity. Differential scanning calorimetry showed increased thermal stability for some of the designs. Finally, the asymmetric nature of the introduced charged mutations allowed for separation of homodimeric impurities by ion exchange chromatography, providing, as an added benefit, a purification strategy for the production of bispecific antibodies with reduced or silenced effector function.http://www.mdpi.com/2073-4468/6/2/7Fc engineeringasymmetric bispecific antibodyion exchange chromatographyknock-out effector function |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Eric Escobar-Cabrera Paula Lario Jason Baardsnes Joseph Schrag Yves Durocher Surjit Dixit |
spellingShingle |
Eric Escobar-Cabrera Paula Lario Jason Baardsnes Joseph Schrag Yves Durocher Surjit Dixit Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function Antibodies Fc engineering asymmetric bispecific antibody ion exchange chromatography knock-out effector function |
author_facet |
Eric Escobar-Cabrera Paula Lario Jason Baardsnes Joseph Schrag Yves Durocher Surjit Dixit |
author_sort |
Eric Escobar-Cabrera |
title |
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function |
title_short |
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function |
title_full |
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function |
title_fullStr |
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function |
title_full_unstemmed |
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function |
title_sort |
asymmetric fc engineering for bispecific antibodies with reduced effector function |
publisher |
MDPI AG |
series |
Antibodies |
issn |
2073-4468 |
publishDate |
2017-05-01 |
description |
Asymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require antibodies with reduced or silenced effector function. Although many solutions have been described in the literature to knockout effector function, to date all of them have involved the use of a specific antibody subtype (e.g., IgG2 or IgG4), or symmetric mutations in the lower hinge or CH2 domain of traditional homodimeric monospecific antibodies. In the context of a heterodimeric Fc, we describe novel asymmetric Fc mutations with reduced or silenced effector function in this article. These heteromultimeric designs contain asymmetric charged mutations in the lower hinge and the CH2 domain of the Fc. Surface plasmon resonance showed that the designed mutations display much reduced binding to all of the Fc gamma receptors and C1q. Ex vivo ADCC and CDC assays showed a consistent reduction in activity. Differential scanning calorimetry showed increased thermal stability for some of the designs. Finally, the asymmetric nature of the introduced charged mutations allowed for separation of homodimeric impurities by ion exchange chromatography, providing, as an added benefit, a purification strategy for the production of bispecific antibodies with reduced or silenced effector function. |
topic |
Fc engineering asymmetric bispecific antibody ion exchange chromatography knock-out effector function |
url |
http://www.mdpi.com/2073-4468/6/2/7 |
work_keys_str_mv |
AT ericescobarcabrera asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction AT paulalario asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction AT jasonbaardsnes asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction AT josephschrag asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction AT yvesdurocher asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction AT surjitdixit asymmetricfcengineeringforbispecificantibodieswithreducedeffectorfunction |
_version_ |
1725763557696471040 |